Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women

Tsiodras, Sotirios; Georgoulakis, J.; Chranioti, Aikaterini; Voulgaris, Z.; Psyrri, Amanda; Tsivilika, Angeliki; Panayiotides, John; Karakitsos, Petros

doi:10.1186/1471-2407-10-53

Cited by 34 publications

(38 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies on human cervical samples have shown similar HPV detection results by PCR using L1 consensus primers (MY09/ MY11 or GP5+/GP6+) (Peyton et al, 1998;Bozzetti et al, 2001). The HC2 had greater positive likelihood ratios than PCR while PCR had negative likelihood ratios than HC2 in cytological grade severity than LSIL (Tsiodras et al, 2010;Comar et al, 2012).…”

Section: Discussionsupporting

confidence: 56%

Clinical Prediction Based on HPV DNA Testing by Hybrid Capture 2 (HC2) in Combination with Liquid-based Cytology (LBC)

Junyangdikul

Tanchotsrinon²,

Chansaenroj³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Primary screening by HPV DNA testing is an effective method for reducing cervical cancer and has proven more sensitive than cytology. To advance this approach, many molecular methods have been developed. Hybrid capture 2 provides semi-quantitative results in ratios of relative light units and positive cutoff values (RLU/ PC). Twenty-five thousand and five patients were included in this study to analyze the correlation between the ratio of RLU/PC and stage of cervical dysplasia. The results show that the RLU/PC ratios ranged from 0-3500 while almost normal cases, ASC-US and ASC-H, had values below 200. Of those samples negative for cytology markers, 94.6% were normal and their RLU/PC ratios were less than 4. With an RLU/PC ratio greater than 4 and less than or equal to 300, the percentages in all age groups were normal 53.6%, LSIL 20.2%, ASC-US 17.2%, HSIL 6.13%, ASC-H 2.72%, and AGC 0.11%, respectively. In contrast, 64.0% of samples with a RLU/ PC ratio greater than 300 and less than or equal to 3500 were LSIL. These results should contribute to cost effective cervical cancer management strategies. Further studies of associations with particular HPV genotypes would be useful to predict the risk of progression to cancer.

show abstract

Section: Discussionsupporting

confidence: 56%

Clinical Prediction Based on HPV DNA Testing by Hybrid Capture 2 (HC2) in Combination with Liquid-based Cytology (LBC)

Junyangdikul

Tanchotsrinon²,

Chansaenroj³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…49 This statement does not reflect results from published studies on cervical cancer patients tested with FDA-approved HPV methods. 35,48,51 Other reports suggest that chemicals in one widely utilized liquid cytology vial (not cleared by the FDA for HPV testing) can cause problematic HPV DNA degradation and/or irreversible fixation. 52,53 Retrospective reviews of Papanicolaou tests preceding cervical cancer diagnoses are often the object of interpretive disputes between the original reviewing cytotechnologist or cytopathologist and cytotechnologists and/or cytopathologists hired by the defense and plaintiff's counsels.…”

Section: Austin and Zhaomentioning

confidence: 98%

Observations From Pap Litigation Consultations

Austin

Zhao

2011

Pathology Case Reviews

View full text Add to dashboard Cite

Papanicolaou test litigation in the United States reflects widespread societal expectations that even occasional cervical screening should prevent nearly all cervical cancers in screened women. Scientific evidence clearly shows that these expectations are unfounded, especially for increasingly prevalent glandular cervical cancers and for more rapidly progressive cervical cancers in younger women. Reviews of Papanicolaou test slides involved in litigation repeatedly show 1 or more of 3 cytologic patterns: difficult-to-interpret abnormal glandular cell groups, difficult-tointerpret hyperchromatic crowded cell groups, and/or difficult-to-locate or -interpret abnormal immature metaplastic squamous cells. Multipleslide blinded reviews, supported by professional organization guidelines, should be used to identify and differentiate culpable medical errors from factors primarily associated with the inherent limitations of human screening and interpretation. In the authors' opinion, remaining US cases of cervical cancer are most likely to be prevented or minimized by more widespread utilization of cotesting with US Food and Drug AdministrationYapproved methods of liquid-based cytology and high-risk human papillomavirus DNA testing.T he Papanicolaou test is the most successful cancer screening test in medical history. 1 The twin goals of cervical screening are (1) to detect and ablate cervical precancer and (2) to detect and minimize the stage at diagnosis of cases of already invasive cervical cancer. 2 Papanicolaou test litigation consultations provide opportunities for valuable insights into both the natural history of cervical carcinogenesis and the limitations of current cervical screening methods and practices. 3 Although the demonstrated capability of cytology-based screening to detect and prevent or downstage invasive cervical cancer (CxCa) is significantly less for both glandular cervical cancers 4,5 and for more rapidly progressive cervical cancers in younger women, 6 there is, nevertheless, a strong public presumption that almost any cervical screening should essentially guarantee that almost all cervical cancers will be prevented. 3 This presumption that cervical screening should prevent almost all cervical cancers in screened women forms the basis for screened patients' consideration of legal recourse after a cervical cancer diagnosis. In our opinion, the same unfounded presumption that cervical screening should reliably prevent almost all cervical cancers strongly influences most consultants asked by plaintiffs to review durable slide evidence after a diagnosis of CxCa and to ascertain whether a culpable medical error occurred. The multiple-slide blinded rescreening (MSBR) method 3,7Y10 has been developed to improve the objectivity of retrospective reviews of litigated Papanicolaou cases and has had some success in helping to adjudicate and resolve disputed cases. Newer cervical screening technologies also have the potential to help achieve cervical screening performance and outcomes that more closely approach...

show abstract

“…In Greece, two molecular methods of HPV detection were used in a large sample of women (Tsiodras et al, 2010). The two methods were: commercially available HC2 and an in house PCR using consensus primers GP5+/6+.…”

Section: Southern Europementioning

confidence: 99%